Share:
CAMBRIDGE, Mass. and INCHEON, South Korea, May 22, 2021 /PRNewswire/ Moderna (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Samsung Biologics (KRX: 207940.KS), a leading global CDMO providing a fully integrated end-to-end contract development and manufacturing service, today announced a Manufacturing Services and Supply Agreement in which Samsung Biologics will provide large scale, commercial fill-finish manufacturing for mRNA-1273, Moderna s COVID-19 vaccine.
Upon execution of the deal, technology transfer will commence immediately at Samsung Biologics facilities in Incheon, South Korea, utilizing a state-of-the-art production line equipped for aseptic fill-finish, labeling, and packaging services to support the production of hundreds of millions of doses of Moderna s COVID-19 vaccine intended for the supply of markets outside of the U.S. starting in the third quarter of 2021.
The agreement will further enable global supply of mRNA-1273, Moderna’s COVID-19 vaccine with Samsung Biologics’ fill and finish manufacturing service
. | May 22, 2021
Article content
The U.S. drugmakers Moderna Inc and Novavax Inc on Saturday entered into a deal with the South Korean government to manufacture their COVID-19 vaccines, as the country has been under pressure to secure more and faster deliveries of U.S.-made vaccines.
The agreements came a day after U.S. President Joe Biden said that he and South Korean President Moon Jae-in had agreed on a comprehensive partnership on COVID-19 vaccines and that the United States would provide vaccinations for 550,000 South Korean soldiers.
We apologize, but this video has failed to load.
Try refreshing your browser, or